j8typz 发表于 2024-10-10 07:07:09

独家 | 自己抗体(第三版)要点分享(连载七):自己免疫性肝炎的自己抗体、抗组织转谷氨酰胺酶......


    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz/KC4lHgxBOkEWfBQXwPmicITTib1l3icxibpTXT5xZQsVcqthUvy0ZqJ5yiaicuxkIdhNib9KpD7uh5y9iazQyCKf3dNibRg/640?wx_fmt=gif&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1" style="width: 50%; margin-bottom: 20px;"></p><img src="https://mmbiz.qpic.cn/mmbiz_png/KC4lHgxBOkFv3zlGRxbVVezW0pHlQSJJLJxoYpUePMOU6Db20Nfb5YWvH1uBlVOUyx8MaxA8Os7dpOibjtufSBw/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">《<span style="color: black;">自己</span>抗体》(第三版)</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2014年,《Autoantibodies(<span style="color: black;">自己</span>抗体)》第三版正式出版,新版本仍以<span style="color: black;">第1</span>版书为框架,<span style="color: black;">然则</span><span style="color: black;">因为</span><span style="color: black;">自己</span>抗体<span style="color: black;">行业</span>的快速发展,内容进行了全面更新。风湿界在接下来几周中,将连载《<span style="color: black;">自己</span>抗体》(第三版)的章节要点(中英文对照)。敬请关注!</p><img src="https://mmbiz.qpic.cn/mmbiz_png/KC4lHgxBOkFv3zlGRxbVVezW0pHlQSJJWOdWfdTASb6LSiaKaL0sVibuncBzdDIeiaibIeAgzvQCok7oZ4G5Wqp3yg/640?wx_fmt=png&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;">
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">作者:</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Yehuda Shoenfeld(以色列特拉维夫大学)</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">Pier Luigi Meroni (意大利米兰大学)</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">M.&nbsp;Eric Gershwin (美国加利福尼亚大学)</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">译者:</strong>黄志坚</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">邮箱:</strong>64847775@qq.com</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">译者注:</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">1.<span style="color: black;">因为</span>国内尚未有中文版《<span style="color: black;">自己</span>抗体(第三版)》出版,<span style="color: black;">自己</span>摘录英文版中章节要点并翻译成中文与<span style="color: black;">大众</span>共享。<span style="color: black;">自己</span>英语水平有限,欢迎<span style="color: black;">大众</span>吐槽。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">2.本连载仅供学习用,请勿用于<span style="color: black;">商场</span>目的。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">3.原版书籍中大部分章节有要点总结,但并不是所有章节都有。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第53章 &nbsp;</strong><strong style="color: blue;"><span style="color: black;">自己</span>免疫性肝炎的<span style="color: black;">自己</span>抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• <span style="color: black;">针对</span>准确诊断<span style="color: black;">自己</span>免疫性肝炎(AIH)以及将<span style="color: black;">自己</span>免疫性肝炎(AIH)适当区分为其两个<span style="color: black;">重点</span>亚型,<span style="color: black;">靠谱</span>和<span style="color: black;">快速</span>检测<span style="color: black;">自己</span>抗体血清阳性是至关重要的。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">•&nbsp;<span style="color: black;">近期</span>,基于<span style="color: black;">运用</span>纯化或重组抗原的分子测定<span style="color: black;">弥补</span>了间接免疫荧光的常规<span style="color: black;">自己</span>抗体检测,但间接免疫荧光仍然是<span style="color: black;">自己</span>免疫血清学的支柱。尽管抗LKM-1和抗LC-1<span style="color: black;">已然</span>被确定为II型<span style="color: black;">自己</span>免疫性肝炎的特定分子靶点,<span style="color: black;">然则</span>用于鉴定II型<span style="color: black;">自己</span>免疫性肝炎的抗核抗体(ANA)和抗平滑肌抗体(SMA)需要更好的定义。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">•&nbsp;尽管<span style="color: black;">自己</span>抗体检测在自身免疫性肝炎中<span style="color: black;">拥有</span>诊断和预后<span style="color: black;">功效</span>,但每种抗体对肝<span style="color: black;">损害</span>的致病<span style="color: black;">功效</span>和潜在贡献仍然是有待进一步<span style="color: black;">科研</span>的课题。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 53&nbsp;Autoantibodies in Autoimmune Hepatitis</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Reliable and prompt detection of autoantibody seropositivity is critical for the accurate diagnosis of AIH and the appropriate differentiation of AIH into its two main subtypes.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Molecular assays based on the use of purified or recombinant antigen have recently complemented routine autoantibody testing by indirect IFL, which, however, remains the autoimmune serology mainstay. Although the specific molecular targets of anti-LKM-1 and anti-LC-1 in AIH-II have been clearly identified, those of ANA and SMA, characterizing AIH-II, require better definition.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Despite the diagnostic and prognostic utility of autoantibody detection in AIH, the pathogenic role and potential contribution of each antibody to liver damage remains a topic for further research.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第54章 &nbsp;</strong><strong style="color: blue;">抗组织转谷氨酰胺酶和抗肌内膜抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 大约0.5-1%的西欧和北美人群<span style="color: black;">身患</span>乳糜泻(CD),其中抗组织转谷氨酰胺酶抗体和抗肌内膜抗体(EMA)是<span style="color: black;">重点</span>的免疫学指标。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• <span style="color: black;">运用</span>人提取或重组组织转谷氨酰胺酶的免疫测定法检测抗组织转谷氨酰胺酶IgA和IgG<span style="color: black;">拥有</span>高灵敏度和特异性水平(分别为91-99%和94-100%)。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 用于鉴定抗组织转谷氨酰胺酶抗体的免疫测定<span style="color: black;">办法</span>的高灵敏度,这使得越来越多的乳糜泻<span style="color: black;">病人</span>能够被鉴定,这些<span style="color: black;">病人</span><span style="color: black;">一般</span><span style="color: black;">拥有</span>模糊或无症状的临床表现。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 54 Antitissue Transglutaminase and Antiendomysial Antibodies</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Approximately 0.5–1% of the western European and North American populations suffer from CD, for which anti-tTG antibodies and EMA are the main immunoserologic markers.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Immunometric methods for the detection of anti-tTG IgA and IgG that use human extractive or recombinant tTG present high sensitivity and specificity levels (91–99% and 94–100%, respectively).</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• The high sensitivity of immunometric methods used to identify anti-tTG antibodies has enabled&nbsp;an increasing number of patients with CD, often with vague or asymptomatic clinical presentations,to be identified.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第55章 &nbsp;&nbsp;</strong><strong style="color: blue;">抗醇溶蛋白和抗脱酰胺醇溶蛋白肽抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 近年来,<span style="color: black;">因为</span>引入了更灵敏和特异的抗谷氨酰胺转氨酶<span style="color: black;">实验</span>,抗醇溶蛋白抗体(AGA)失去了许多诊断<span style="color: black;">道理</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 然而,<span style="color: black;">近期</span><span style="color: black;">运用</span>由合成的脱酰胺醇溶蛋白肽(DGP)<span style="color: black;">构成</span>的涂层的ELISA测试<span style="color: black;">表示</span>出良好的诊断准确性,与抗转谷氨酰胺酶测试相当。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 抗脱酰胺醇溶蛋白肽(DGP)抗体测定<span style="color: black;">针对</span>2-3岁以下<span style="color: black;">病人</span>的乳糜泻(CD)诊断<span style="color: black;">尤其</span>有用,<span style="color: black;">由于</span>抗转谷氨酰胺酶抗体可能在<span style="color: black;">很强</span>年龄<span style="color: black;">显现</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• <span style="color: black;">针对</span>IgA缺乏症<span style="color: black;">病人</span>,脱酰胺醇溶蛋白肽(DGP)IgG 的阳性<span style="color: black;">亦</span>很重要,<span style="color: black;">由于</span>它可能是<span style="color: black;">独一</span>的阳性血清学标志物(与抗组织转谷氨酰胺酶 IgG<span style="color: black;">关联</span>)。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 在<span style="color: black;">无</span>抗肌内膜抗体,而抗醇溶蛋白IgG和IgA抗体阳性的<span style="color: black;">状况</span>下,抗转谷氨酰胺酶IgA、脱酰胺醇溶蛋白肽IgA或IgG可用作<span style="color: black;">病人</span>可能对非乳糜泻麸质<span style="color: black;">敏锐</span>症(GS)的指标。<span style="color: black;">病人</span>的肠或肠外症状提示其<span style="color: black;">身患</span>麸质<span style="color: black;">关联</span><span style="color: black;">疾患</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 55 Antigliadin and Antideamidated Gliadin Peptide Antibodies</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• AGA have lost much of their diagnostic significance in recent years due to the introduction of the more sensitive and specific anti transglutaminase test.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• However, recent ELISA tests that use a coating consisting of synthetic deamidated gliadin peptides (DGP) show good diagnostic accuracy, comparable to those of the anti transglutaminase test.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Anti-DGP antibody determination is especially useful for CD diagnosis in patients under 2–3 years old, as anti transglutaminase antibodies may appear at an older age.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">•&nbsp;Positivity for IgG DGP can also be important in patients with IgA deficiency, in whom it may be the only positive serologic marker (in association with anti-tTG IgG).</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">•&nbsp;Positivity for IgG and IgA-type AGA, in the absence of EMA, IgA anti transglutaminase, IgA, or IgG DGP can be used as an indicator of possible nonceliac GS in patients with intestinal or extraintestinal symptoms suggestive of this gluten-related disorder.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第56章 &nbsp;</strong><strong style="color: blue;">肝胞浆1型抗原(LC-1)<span style="color: black;">自己</span>抗体,肝肾微粒体(LKM)<span style="color: black;">自己</span>抗体和肝微粒体(LM)<span style="color: black;">自己</span>抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 在啮齿动物冷浴肝肾切片上,<span style="color: black;">经过</span>间接免疫荧光检测肝肾微粒体(LKM)<span style="color: black;">自己</span>抗体。这用作筛查工具。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 需要<span style="color: black;">运用</span>重组抗原进行亚<span style="color: black;">归类</span>,以确定微粒体<span style="color: black;">自己</span>抗体的特异性。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 内质网(ER)的<span style="color: black;">药品</span>代谢酶是<span style="color: black;">疾患</span>特异性B细胞反应性的<span style="color: black;">重点</span><span style="color: black;">目的</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• <span style="color: black;">经过</span>免疫扩散和与甲酰转移酶环化脱氨酶的反应性检测肝胞浆1型抗原(LC-1)<span style="color: black;">自己</span>抗体。间接免疫荧光法并不<span style="color: black;">靠谱</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 与抗微粒体抗体<span style="color: black;">关联</span>的<span style="color: black;">疾患</span><span style="color: black;">包含</span><span style="color: black;">药品</span>诱导的肝炎、病毒性肝炎、<span style="color: black;">自己</span>免疫性肝炎(AIH)和1型<span style="color: black;">自己</span>免疫性多腺体<span style="color: black;">综合症</span>(APECED,APS-1)。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 肝肾微粒体(LKM)和肝胞浆1型抗原(LC-1)抗体是<span style="color: black;">自己</span>免疫性肝炎的部分常规诊断性抗体。LKM-3和LKM-2和肝微粒体(LM)<span style="color: black;">自己</span>抗体是有用的诊断工具。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 56 Liver Cytosol Antigen Type 1&nbsp;Autoantibodies (LC-1), Liver Kidney Microsomal&nbsp;Autoantibodies (LKM), and Liver&nbsp;Microsomal Autoantibodies (LM)</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Liver kidney microsomal (LKM) autoantibodies are detected by indirect immunofluorescence on&nbsp;rodent cryostat liver and kidney sections, which are employed as screening tools.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Subclassification using recombinant antigens is required to determine the specificity of&nbsp;microsomal&nbsp;autoantibodies.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Drug-metabolizing enzymes of the ER are major targets of disease-specific B-cell reactivities.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• LC-1 autoantibodies are detected by immunodiffusion and reactivity with formiminotransferase&nbsp;cyclodeaminase and not reliably by indirect immunofluorescence.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Disease associations of antimicrosomal antibodies include drug-induced hepatitis, viral hepatitis, AIH, and the autoimmune polyglandular syndrome type 1 (APECED, APS-1).</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• LKM and LC1 antibodies are part of the conventional repertoire of diagnostic antibodies for AIH, LKM-3, and LKM-2, and LM autoantibodies are useful diagnostic tools.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第57章 &nbsp;</strong><strong style="color: blue;">抗线粒体抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 血清中的抗线粒体抗体(AMA)是原发性胆汁性肝硬化的标志。<span style="color: black;">经过</span>间接免疫荧光<span style="color: black;">发掘</span>90-95%的病例中存在这种抗体。</p>

    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 抗线粒体抗体的靶抗原已被鉴定为在糖酵解和氨基酸代谢中起<span style="color: black;">功效</span>的复合物。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 抗线粒体抗体的致病<span style="color: black;">功效</span>仍然未知,<span style="color: black;">由于</span>抗线粒体抗体阴性病例<span style="color: black;">无</span><span style="color: black;">区别</span>的<span style="color: black;">疾患</span>表型。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 检测抗线粒体抗体的常规<span style="color: black;">办法</span>是在大鼠肾、胃和肝组织上进行间接免疫荧光,而基于更特异的重组抗原的其他技术的<span style="color: black;">运用</span>仅限于选定的病例。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 缺乏血清抗线粒体抗体的原发性胆汁性肝硬化被<span style="color: black;">叫作</span>为<span style="color: black;">自己</span>免疫性胆管炎。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 57 Antimitochondrial Antibodies</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Serum AMA are the hallmark of PBC, being found at IIF in 90–95% of cases.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">•&nbsp;AMA antigens have been identified as complexes active in the glycolytic and amino acid&nbsp;metabolism.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• The pathogenetic role of AMA remains unknown, as AMA-negative cases do not have a different&nbsp;disease phenotype.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• The routine method for AMA detection is IIF on rat kidney, stomach, and liver tissues, while the&nbsp;use of other techniques based on the more specific recombinant antigens is limited to selected&nbsp;cases.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Proven PBC lacking serum AMA is called autoimmune cholangitis.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第58章 &nbsp;</strong><strong style="color: blue;">平滑肌<span style="color: black;">自己</span>抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 平滑肌<span style="color: black;">自己</span>抗体(SMA)<span style="color: black;">表率</span>了针对<span style="color: black;">区别</span>细胞骨架<span style="color: black;">成份</span>的大范围<span style="color: black;">自己</span>反应,其中肌动蛋白是<span style="color: black;">科研</span>最多且临床<span style="color: black;">关联</span>的<span style="color: black;">成份</span>。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 大鼠组织的间接免疫荧光仍然是检测平滑肌<span style="color: black;">自己</span>抗体和鉴定抗肌动蛋白特异性的最<span style="color: black;">敏锐</span>和特异的技术; 然而,<span style="color: black;">运用</span>丝状肌动蛋白的有前途且<span style="color: black;">靠谱</span>的酶联免疫吸附法(ELISA)测定正在<span style="color: black;">研发</span>中。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 平滑肌<span style="color: black;">自己</span>抗体在<span style="color: black;">自己</span>免疫性肝炎(AIH)的诊断中<span style="color: black;">拥有</span><span style="color: black;">关联</span>的诊断<span style="color: black;">功效</span>,但缺乏预后<span style="color: black;">道理</span>。相反,在乳糜泻中,<span style="color: black;">拥有</span>抗肌动蛋白特异性的IgA类平滑肌<span style="color: black;">自己</span>抗体与严重的粘膜<span style="color: black;">损害</span><span style="color: black;">关联</span>,并可能有助于监测对无麸质<span style="color: black;">膳食</span>的反应。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 58 Smooth Muscle Autoantibodies</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• SMA represent a large spectrum of autoreactivities targeting different cytoskeleton components,&nbsp;of which actin is the most studied and clinically relevant.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• IIF on rat tissues still represents the most sensitive and specific technique to detect SMA and&nbsp;identify antiactin specificity; however, promising and reliable ELISA assays with filamentous&nbsp;actin are being developed.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• SMA have a relevant diagnostic role in the diagnosis of AIH but are devoid of prognostic significance.In contrast, in celiac disease SMA of IgA class with antiactin specificity correlates with&nbsp;severe mucosal damage and may be helpful in monitoring the response to gluten-free diet.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">第59章&nbsp;</strong><strong style="color: blue;">凝血因子<span style="color: black;">自己</span>抗体</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• <span style="color: black;">因为</span>抗凝血因子<span style="color: black;">自己</span>抗体<span style="color: black;">导致</span>的<span style="color: black;">流血</span>性<span style="color: black;">疾患</span>很少见;然而,其中,最<span style="color: black;">平常</span>的是抗凝血因子VIII<span style="color: black;">自己</span>抗体。由<span style="color: black;">自己</span>抗体<span style="color: black;">导致</span>血管性血友病因子和因子XIII的缺陷是突发<span style="color: black;">状况</span>。其他凝血因子的抗体是非常罕见的,仅在零散的报告中描述。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 在<span style="color: black;">身患</span>个人和家族<span style="color: black;">流血</span>史阴性的<span style="color: black;">病人</span><span style="color: black;">流血</span>时,应怀疑潜在的凝血因子<span style="color: black;">自己</span>抗体,并<span style="color: black;">最后</span><span style="color: black;">经过</span>特定的实验室<span style="color: black;">检测</span>确认。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 确认临床可疑凝血因子<span style="color: black;">自己</span>抗体的诊断测试是<span style="color: black;">血液</span>凝血酶原时间(PT),活化部分凝血活酶时间(aPTT),混合<span style="color: black;">科研</span>和特定测定。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• 一旦确认凝血因子<span style="color: black;">自己</span>抗体的存在,治疗的目的应该是在<span style="color: black;">流血</span>的<span style="color: black;">状况</span>下替换或克服缺陷因子,消除<span style="color: black;">自己</span>抗体并<span style="color: black;">控制</span>其生成。</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">CHAPTER 59 Coagulation Factor Autoantibodies</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Bleeding disorders due to autoantibodies against coagulation factors are rare; however,&nbsp;among them, the most frequent are related to antifactor VIII autoantibodies. Acquired&nbsp;deficiencies of von Willebrand factor and factor XIII due to autoantibodies are emerging&nbsp;conditions. Antibodies to other coagulation factors are very rare and described only in&nbsp;scattered reports.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• In the presence of bleeding in patients with a negative personal and family hemorrhagic history,&nbsp;an underlying coagulation factor autoantibody should be suspected and eventually confirmed by&nbsp;specific laboratory tests.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• The diagnostic tests to confirm the clinical suspicion of coagulation factor autoantibody are PT,&nbsp;aPTT, mixing studies, and specific assays.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;">• Once the presence of coagulation factor autoantibodies has been confirmed, the therapy should be&nbsp;aimed at the replacement or overcoming of the deficient factor in case of bleeding and at the&nbsp;elimination of the autoantibody as well as the suppression of its production.</p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">周<span style="color: black;">2、</span>周四</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><strong style="color: blue;">关注《<span style="color: black;">自己</span>抗体》(第三版)要点分享连载!</strong></p>
    <p style="font-size: 16px; color: black; line-height: 40px; text-align: left; margin-bottom: 15px;"><img src="https://mmbiz.qpic.cn/mmbiz/KC4lHgxBOkG7Y294vYBJ45AdypAnU0e2NAArRglibwib3urjiaJJ9vo8Y8AQvpDPBx8ciczunqlxVAuoNPWgcak9ibg/640?wx_fmt=jpeg&amp;tp=webp&amp;wxfrom=5&amp;wx_lazy=1&amp;wx_co=1" style="width: 50%; margin-bottom: 20px;"></p>




m5k1umn 发表于 2024-10-29 09:42:26

“BS”(鄙视的缩写)‌
页: [1]
查看完整版本: 独家 | 自己抗体(第三版)要点分享(连载七):自己免疫性肝炎的自己抗体、抗组织转谷氨酰胺酶......